Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction.

[1]  A. Skene,et al.  Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease , 2007, Diabetes Care.

[2]  A. Lincoff,et al.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.

[3]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[4]  A. Skene,et al.  The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. , 2007, Journal of the American College of Cardiology.

[5]  J. McMurray,et al.  A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. , 2007, Journal of the American College of Cardiology.

[6]  D. Betteridge,et al.  Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) , 2007, Stroke.

[7]  Karl Swedberg,et al.  Adjudication of serious heart failure in patients from PROactive , 2007, The Lancet.

[8]  Clare Chapman.  Doctors' strikes blamed for patient's death in Germany , 2006, The Lancet.

[9]  Alfonso T. Perez,et al.  Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy , 2006, Diabetes & vascular disease research.

[10]  D. Mukhopadhyay,et al.  Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. , 2006, Diabetes care.

[11]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[12]  A. D'Angelo,et al.  Thiazolidinedione Effects on Blood Pressure in Diabetic Patients with Metabolic Syndrome Treated with Glimepiride , 2005, Hypertension Research.

[13]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[14]  Ross T Tsuyuki,et al.  Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. , 2005, Diabetes care.

[15]  Reena Rao,et al.  Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption , 2005, Nature Medicine.

[16]  Rob Hyde.  Germany plans to lure doctors back from west to east , 2005, The Lancet.

[17]  D. Kohan,et al.  Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Alfonso T. Perez,et al.  A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. , 2005, Diabetes care.

[19]  C. Gullion,et al.  The incidence of congestive heart failure in type 2 diabetes: an update. , 2004, Diabetes care.

[20]  G. Reaven.  Metabolic Syndrome: Pathophysiology and Implications for Management of Cardiovascular Disease , 2002, Circulation.

[21]  G. Moneta.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialDormandy JA, for the PROactive investigators (St Georges Hosp, London; et al) Lancet 366:1279–1289, 200 , 2007 .

[22]  J. Leahy.  Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure , 2006 .

[23]  G. Koch,et al.  Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. , 2005, Diabetes care.

[24]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .